A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies

Joshua R. Gonzalez, Melissa A. Laudano, Tara R. McCann, James M. McKiernan, Mitchell C. Benson

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

High-risk, localized prostate cancer represents a complex and diverse disease with many available treatment modalities. Patients are often deemed high risk because they are at increased risk for biochemical failure after primary intervention. However, these "high-risk" men may not be at significant risk of dying from their cancer. In this review, an attempt will be made to better define high-risk patients and help identify men at increased risk for mortality, not simply biochemical failure, after a diagnosis of localized prostate cancer. A review of available monotherapies as well as previously successful multimodality treatments will also be presented. Finally, this review will provide a glimpse into the future direction of high-risk prostate cancer multimodal therapy by providing a synopsis several current randomized clinical trials using effective systemic adjuvant therapies following local treatment.

Original languageEnglish (US)
Pages (from-to)475-480
Number of pages6
JournalWorld Journal of Urology
Volume26
Issue number5
DOIs
StatePublished - Sep 3 2008
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Therapeutics
Randomized Controlled Trials
Mortality
Neoplasms

Keywords

  • Adjuvant therapy
  • High risk
  • Prostate
  • Prostatic neoplasia
  • Radical prostatectomy
  • Survival

ASJC Scopus subject areas

  • Urology

Cite this

A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies. / Gonzalez, Joshua R.; Laudano, Melissa A.; McCann, Tara R.; McKiernan, James M.; Benson, Mitchell C.

In: World Journal of Urology, Vol. 26, No. 5, 03.09.2008, p. 475-480.

Research output: Contribution to journalReview article

Gonzalez, Joshua R. ; Laudano, Melissa A. ; McCann, Tara R. ; McKiernan, James M. ; Benson, Mitchell C. / A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies. In: World Journal of Urology. 2008 ; Vol. 26, No. 5. pp. 475-480.
@article{97f6e66c35a74a58bbbbf35641d0a744,
title = "A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies",
abstract = "High-risk, localized prostate cancer represents a complex and diverse disease with many available treatment modalities. Patients are often deemed high risk because they are at increased risk for biochemical failure after primary intervention. However, these {"}high-risk{"} men may not be at significant risk of dying from their cancer. In this review, an attempt will be made to better define high-risk patients and help identify men at increased risk for mortality, not simply biochemical failure, after a diagnosis of localized prostate cancer. A review of available monotherapies as well as previously successful multimodality treatments will also be presented. Finally, this review will provide a glimpse into the future direction of high-risk prostate cancer multimodal therapy by providing a synopsis several current randomized clinical trials using effective systemic adjuvant therapies following local treatment.",
keywords = "Adjuvant therapy, High risk, Prostate, Prostatic neoplasia, Radical prostatectomy, Survival",
author = "Gonzalez, {Joshua R.} and Laudano, {Melissa A.} and McCann, {Tara R.} and McKiernan, {James M.} and Benson, {Mitchell C.}",
year = "2008",
month = "9",
day = "3",
doi = "10.1007/s00345-008-0314-8",
language = "English (US)",
volume = "26",
pages = "475--480",
journal = "World Journal of Urology",
issn = "0724-4983",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - A review of high-risk prostate cancer and the role of neo-adjuvant and adjuvant therapies

AU - Gonzalez, Joshua R.

AU - Laudano, Melissa A.

AU - McCann, Tara R.

AU - McKiernan, James M.

AU - Benson, Mitchell C.

PY - 2008/9/3

Y1 - 2008/9/3

N2 - High-risk, localized prostate cancer represents a complex and diverse disease with many available treatment modalities. Patients are often deemed high risk because they are at increased risk for biochemical failure after primary intervention. However, these "high-risk" men may not be at significant risk of dying from their cancer. In this review, an attempt will be made to better define high-risk patients and help identify men at increased risk for mortality, not simply biochemical failure, after a diagnosis of localized prostate cancer. A review of available monotherapies as well as previously successful multimodality treatments will also be presented. Finally, this review will provide a glimpse into the future direction of high-risk prostate cancer multimodal therapy by providing a synopsis several current randomized clinical trials using effective systemic adjuvant therapies following local treatment.

AB - High-risk, localized prostate cancer represents a complex and diverse disease with many available treatment modalities. Patients are often deemed high risk because they are at increased risk for biochemical failure after primary intervention. However, these "high-risk" men may not be at significant risk of dying from their cancer. In this review, an attempt will be made to better define high-risk patients and help identify men at increased risk for mortality, not simply biochemical failure, after a diagnosis of localized prostate cancer. A review of available monotherapies as well as previously successful multimodality treatments will also be presented. Finally, this review will provide a glimpse into the future direction of high-risk prostate cancer multimodal therapy by providing a synopsis several current randomized clinical trials using effective systemic adjuvant therapies following local treatment.

KW - Adjuvant therapy

KW - High risk

KW - Prostate

KW - Prostatic neoplasia

KW - Radical prostatectomy

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=53549104403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53549104403&partnerID=8YFLogxK

U2 - 10.1007/s00345-008-0314-8

DO - 10.1007/s00345-008-0314-8

M3 - Review article

VL - 26

SP - 475

EP - 480

JO - World Journal of Urology

JF - World Journal of Urology

SN - 0724-4983

IS - 5

ER -